# EDGAR Filing Document

**Accession Number:** 0001522860
**File Stem:** 0001628280-23-007637
**Filing Date:** 2023-3
**Character Count:** 5058
**Document Hash:** 026914d8227dd8f8febef2cfd9984e20
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-007637.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001628280-23-007637

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230313

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Acutus Medical, Inc.
- **CENTRAL INDEX KEY:** 0001522860
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 451306615
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39430
- **FILM NUMBER:** 23725805

**BUSINESS ADDRESS:**
- **STREET 1:** 2210 FARADAY AVE
- **STREET 2:** SUITE 100
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92008
- **BUSINESS PHONE:** 442-232-6080

**MAIL ADDRESS:**
- **STREET 1:** 2210 FARADAY AVE
- **STREET 2:** SUITE 100
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92008

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549** 

_________________________________________

**FORM 8-K**

_________________________________________

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): March 13, 2023** 

_________________________________________

![picture1a.jpg](picture1a.jpg)

**Acutus Medical, Inc.**

**(Exact name of Registrant as Specified in Its Charter)** 

_________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39430** | **45-1306615** |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |
| **2210 Faraday Ave., Suite 100**<br>**Carlsbad, CA** | | **92008** |
| **(Address of Principal Executive Offices)** | | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code: (442) 232-6080**

**Not Applicable** 

**(Former Name or Former Address, if Changed Since Last Report)** 

_________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange on Which Registered** |
| Common Stock, par value $0.001 | AFIB | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

**Item 8.01&nbsp;&nbsp;&nbsp;&nbsp;Other Events**

------

On March 10, 2023, Acutus Medical, Inc. ("we" or the "Company") conducted an analysis of its financial exposure stemming from the failure of Silicon Valley Bank ("SVB") and subsequent appointment of the Federal Deposit Insurance Corporation (the "FDIC") as receiver and had assessed the Company's exposure to be immaterial. On March 12, 2023, the Department of the Treasury, Board of Governors of the Federal Reserve System and the FDIC approved actions enabling the FDIC to complete its resolution of SVB in a manner that fully protects all depositors. We are confident that the Company will have full access to its cash and investments. Additionally, the Company is evaluating its financial business partners to ensure long-term security of its assets.

**Item 9.01.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

(d)Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 104.0 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **Acutus Medical, Inc.** | **Acutus Medical, Inc.** |
| Date: March 13, 2023 | By: | /s/ Tom Sohn |
|  |  | Tom Sohn |
|  |  | SVP, General Counsel |

---